Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Agios Pharmaceuticals
(NQ:
AGIO
)
34.54
-0.04 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Agios Pharmaceuticals
< Previous
1
2
3
Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
July 27, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
July 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
U.S. Stock Futures Higher; All Eyes On Inflation Data
July 13, 2022
Pre-open movers
Via
Benzinga
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
May 17, 2022
Via
Benzinga
7 Analysts Have This to Say About Agios Pharmaceuticals
May 17, 2022
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Agios Pharmaceuticals: Q1 Earnings Insights
May 05, 2022
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
July 13, 2022
With the US stock futures trading slightly higher this morning on Wednesday after recording losses in the previous session, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 27, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 04, 2022
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Analyst Ratings For Agios Pharmaceuticals
February 22, 2022
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Agios Pharmaceuticals
February 22, 2022
Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...
Via
Benzinga
FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder
February 18, 2022
The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate...
Via
Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...
Via
Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden
December 14, 2021
Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021
December 03, 2021
Upgrades Cowen & Co. upgraded the previous rating for Marvell Technology Inc (NASDAQ:
Via
Benzinga
This Company Says It's One Step Closer to Transforming Cancer Treatment with its Latest Groundbreaking Immunotherapy
November 11, 2021
Photo by Martha Dominguez de Gouveia on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Agios Pharmaceuticals, inc (AGIO) Q3 2021 Earnings Call Transcript
November 03, 2021
AGIO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.